Poor in vivo homing capacity of hematopoietic stem/ progenitor cells (HS/PCs) from umbilical cord blood (UCB) can be reversed by short-term ex vivo manipulation with recombinant human stem cell factor (rHuSCF). This study was designed to evaluate the effect of ex vivo manipulation of UCB-derived HS/PCs with rHuSCF on human cell engraftment rates in xenotransplanted NOD/ SCID mouse model. The human cell engraftment rates in xenotransplanted primary and secondary NOD/SCID mice were characterized using four-color flow cytometric analysis and progenitor assay. Grafts of rHuSCF-treated UCB CD34
Summary:
Poor in vivo homing capacity of hematopoietic stem/ progenitor cells (HS/PCs) from umbilical cord blood (UCB) can be reversed by short-term ex vivo manipulation with recombinant human stem cell factor (rHuSCF). This study was designed to evaluate the effect of ex vivo manipulation of UCB-derived HS/PCs with rHuSCF on human cell engraftment rates in xenotransplanted NOD/ SCID mouse model. The human cell engraftment rates in xenotransplanted primary and secondary NOD/SCID mice were characterized using four-color flow cytometric analysis and progenitor assay. Grafts of rHuSCF-treated UCB CD34
þ cells resulted in significantly higher levels of human cell engraftment than that of nontreated ones in both xenotransplanted primary and secondary NOD/ SCID recipients. Fresh UCB CD34 þ cells did not express either of the matrix metalloproteinase (MMP) family members MMP-2 or MMP-9. rHuSCF-treated UCB CD34 þ cells expressed significant levels of MMP-2 and MMP-9. Pretreatment of UCB CD34 þ cells with the specific MMP inhibitor completely blocked human cell engraftment in xenotransplanted NOD/SCID recipients. Our results indicate that ex vivo manipulation of human HS/PCs with rHuSCF might provide an optimal approach to develop more effective stem cell-based therapies in situations where engraftment is delayed due to limiting HS/PCs number, for example, UCB transplantation. Umbilical cord blood (UCB) has been proved to be an alternative hematopoietic stem/progenitor cell (HS/PCs) source for patients without matched sibling donors. [1] [2] [3] [4] Since the initial case, 5 more than 4000 UCB transplants (UCBT) have been performed worldwide to date. However, compared with bone marrow transplantation (BMT) and mobilized peripheral blood stem cell transplantation (mPBSCT) recipients, UCBT recipients have prolonged recovery periods, which are reported to result from delayed neutrophil and platelet recoveries, and there is a documented 10-15% graft failure rate.
1-4 The severely delayed hematopoietic reconstitution of UCBT recipients due to their slow engraftment increased the risks of infectious and bleeding complications. Possible causes include the lower number of HS/PCs infused and the lack of a subpopulation to facilitate HS/PCs engraftment. 3, 4 Recently, Wagner et al 6 clarified the importance of graft CD34 þ cell dose in determining the outcome after unrelated donor UCBTs, proposing a dose of 1.7 Â 10 5 CD34 þ cells/kg of the recipient's body weight as the threshold dose for UCBT recipients. 6 Therefore, the majority of UCBTs have been carried out in children due to limited numbers of HS/PCs in a single UCB unit. The importance of cell dose for UCBT outcomes and clinical applicability provides the most compelling argument for investigating other practical approaches, for example, ex vivo expansion of UCB HS/ PCs, 7, 8 or transplantation of multiple UCB units, 9 or others (if available) in future clinical trials.
Immunodeficient nonobese diabetic NOD/LtSz mice homozygous for the severe combined immunodeficiency Prkdc scid (NOD/SCID) mutation have been shown to be a useful host for xenogeneic human hematopoietic cell grafts. [10] [11] [12] [13] [14] Vormoor et al 10 injected 15-50 Â 10 6 FicolHypaque-treated UCB cells into total body irradiated NOD/SCID mice; they reported greater than 10% engraftment in 39 of the 53 mice at 4 weeks post-injection. Both myeloid and lymphoid engraftment were observed.
To reach a successful engraftment, HSCs must home to their niches in the supportive bone marrow microenvironment, engraft and mature before being released into the circulation. Voermans 16 and that of human UCB competitive repopulating units (CRU) were 7% as determined by limiting-dilution assays. 17 The possible reasons include entrapment of HS/PCs in the liver and/or lung, or inability to home to their niches. Our recent study demonstrated that intrinsic differences in the motility of HS/PCs from different sources, for example, defective ex vivo transmigratory and poor in vivo homing capacity of CD34 þ cells from UCB, do exist. 18 Interestingly, this deficit can be reversed by shortterm ex vivo manipulation of both fresh and cryopreserved UCB-derived CD34 þ cells with recombinant human stem cell factor (rHuSCF).
Herein, we hypothesize that optimal engraftment might be expected from ex vivo manipulation of UCB-derived HS/ PCs with rHuSCF. We examined this hypothesis by characterization of the rate of human engraftment in xenotransplanted NOD/SCID mouse model following ex vivo manipulation of UCB-derived HS/PCs with or without rHuSCF.
Materials and methods
Human UCB collection and mononuclear cell preparation UCB units were collected only from single-birth, full-term, low-risk deliveries. The UCB units were transferred into the laboratory and analyzed within 12 h after collection. All UCB donors signed an informed consent according to the international standards for UCB collection developed by NETCORD, the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT). UCB cell suspensions were diluted 1:3 with phosphate-buffered saline (PBS) containing 2 mmol/l ethylenediaminetetraacetic acid (EDTA) (PBS/EDTA). Mononuclear cells (MNCs) were isolated by gradient centrifugation on Ficoll-Paque (Pharmacia, Uppsala, Sweden) and resuspended in PBS/EDTA.
Purification of human UCB CD34
þ cells
Purification of human CD34
þ cells was performed with a direct CD34 separation kit (autoMACS, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Cell fractions showing a CD34 þ cell purity of 95% or greater were used for subsequent experiments.
Treatment of UCB-derived CD34
Purified CD34 þ cells were incubated at 371C, 5% CO 2 for 48 h at a concentration of 1 Â 10 6 cells/ml in IMDM/10% FBS with or without rHuSCF at 100 ng/ml. CD34 þ cells were then used for in vivo xenotransplantation or analysis of expression of MMP-2 and MMP-9.
Mice NOD/LtSz-Prkdc scid /Prkdc scid (NOD/SCID) mice, 4-6 weeks of age and female, were obtained from the Central Institute for Experimental Animals (Beijing, China) and maintained under specific pathogen-free conditions in individually ventilated (high-efficiency particle-arresting) filtered air at the Experimental Animal Center, Institute of Hematology, CAMS&PUMC, and provided with autoclaved food and water ad libitum. Sentinels were tested routinely for common murine pathogens. Experiments were approved by the Institute of Hematology Animal Care and Use Committee.
Pair xenotransplantation
The 8-week-old female mice were irradiated with a sublethal dose of 2.6 Gy (cobalt 60), and 4 h after irradiation mice were injected aliquots containing 1 Â 10
þ cells from the same UCB unit. As natural killer cell-depleted NOD/SCID mice are more sensitive recipients for human HS/PCs, the recipient mice were injected intraperitoneally with 400 ml PBS containing 20 ml anti-asialo GM1 antiserum (Wako) immediately before xenotransplantation. Identical treatments were repeated on days 11, 22, 33 and 44 after xenotransplantation. Mice were euthanized at specified time points, cells from bone marrow and spleen were flushed into IMDM/10%FBS and put through a Cell Strainer to remove clumps and debris, and were used for subsequent experiments.
Secondary transplantation
All of the cells obtained from the bone marrow and spleen of primarily transplanted NOD/SCID mice in both SCF [À] and SCF[ þ ] groups were transplanted into irradiated secondary NOD/SCID recipients. At 8 weeks after xenotransplantation, the presence of transplanted human cells in recipient bone marrow was analyzed by flow cytometry, as was described for primary recipients.
Assessment of human cell engraftment in NOD-SCID mice
Mice were euthanized at the specified time points postxenotransplantation, cells from bone marrow, spleen and peripheral blood were harvested and assessed for human cell engraftment using flow cytometry and progenitor assays. Engraftment in NOD-SCID mice was defined as the presence of at least 0.1% human CD45 þ cells of total nucleated cells in the murine bone marrow microenvironment, with evidence of multi-lineage reconstitution. Multilineage engraftment was evident by a panel of antibodies to monitor lymphocyte, myeloid, megakaryocytic and HS/ PCs engraftment. Briefly, cells were stained with antimouse CD45-PerCP and anti-human CD45-APC, then dual-labelled with human-specific antibodies, including CD41a-FITC, CD38-FITC, CD33-PE and CD34-PE. Debris was thresholded out, and at least 1 000 000 events were collected and analyzed using FlowJot software (TreeStar, San Carlos, CA, USA). Spiking experiments showed that 0.01% human cells in murine bone marrow and peripheral blood can be reliably detected (data not shown). Percentage human engraftment was calculated by dividing the number of human CD45 þ cells by the total number of CD45 þ cells (human þ mouse), and expressing this ratio as a percentage. The quality of engraftment was calculated by dividing the number of human CD33 þ (or CD34 þ etc) cells by the total number of CD45 þ cells (human þ mouse) and expressing this ratio as a percentage. Human erythroid (BFU-E), granulomonocytic (CFU-GM) and multi-lineage (CFU-Mix)-derived colonies from engrafted mice were performed using human cytokines and plasma for the selective growth of human rather than mouse colonies.
Analyses of expression levels of MMP-2 and MMP-9
Four-color FACS was applied to analyze the expression levels of MMP-2 and MMP-9 on live HS/PCs using FACSCaliburt and CELLQuestt software (BDIS). UCB MNCs were resuspended in staining buffer (PBS, 0.1% human serum albumin and 0.02% sodium azide). After blocking Fc receptors with 0.5% mouse serum (Dako), MNCs were then sequentially stained with either purified anti-human MMP-2 (A-Gel VC2) or anti-human MMP-9 (IIA5) (PharMingen) antibody and PE-conjugated polyclonal anti-mouse Ig (PharMingen). After three times washes, cells were further stained with a combination of CD45-FITC (PharMingen), CD34-APC and propidium iodide (PI, Sigma, St Louis, MO, USA). At least 3 000 000 events were collected and analyzed. The gating scheme was as follows: first gating on the lymphocyte population on FSC vs SSC configuration, and secondary gating on the live CD34 þ cell population on CD34-APC (581) (Immunotech, Marseille, France) vs PI plot, together with matching IgG1-APC (MOPC-21) (BDIS) to determine CD34 bright and CD34 dim subpopulations. The percentages and fluorescence intensities of stained cells were calculated by FlowJot software.
Statistical analysis
Data are presented as the mean7s.e.m. Differences between quantitative measurements among the SCF[À] and SCF[ þ ] group recipients were determined by using the two-tailed Student's t-test, and a P-value o0.05 was considered to be statistically significant.
Results
Ex vivo manipulation of UCB-derived HS/PCs with rHuSCF resulted in higher levels of human hematopoietic cell engraftment in xenotransplanted NOD/SCID mice
We used NOD/SCID mouse model, a useful host for longterm human HS/PCs engraftment, for this study. Aliquots containing 1 Â 10 4 rHuSCF-treated or nontreated CD34 þ cells from the same UCB unit were injected into recipient mice. The level of hematopoietic repopulation is a critical parameter in stem cell transplantation. We examined 8-week engraftment levels of human cells by measuring the percentages of CD45 þ human cells in the bone marrow, spleen and peripheral blood of pair-xenotransplanted NOD/SCID mice given transplants of 1 Â 10 4 CD34 þ cells from the same UCB unit after incubation with or without rHuSCF. Interestingly, xenotransplantation of rHuSCFtreated CD34 þ cells into NOD/SCID mice achieved significantly more superior 8-week-engraftment levels than of nontreated ones (Po0.01) (Figure 1 ).
Higher engraftment in secondary NOD/SCID mice that received grafts of rHuSCF-treated CD34
Long-term engraftment capacity and self-renewal of hematopoietic stem cells can be assessed by serial transplantation. A theory behind this assay is that stem cells which give rise to multilineage hematopoiesis in primary recipients are also capable of repeating this process in recipients of secondary transplants. Engraftment levels in secondary recipients were significantly higher when they received transplants of 1 Â 10 4 rHuSCF-treated CD34 
Discussion
Homing and lodgement of transplanted HS/PCs into a recipient's bone marrow are critical steps during engraftment and initiation of marrow reconstitution. In the first phase 'homing,' transplanted cells must home to vascular sites and need to penetrate the basal lamina that is composed of extracellular matrix (ECM) proteins. Homing has been demonstrated to play pivotal roles during HS/PCs engraftment and hematopoietic reconstitution. 19, 20 The SRCs possess the capacity for transmigration to SDF-1a and the ex vivo motility of human CD34 þ cells correlates with their repopulating potential in patients receiving transplants. 15 Recent studies demonstrated that intrinsic differences in motility of HS/PCs from different sources, for example, poor homing capacity of CD34 þ and CD34 þ CD38 À cells from UCB, do exist. 18, 21, 22 From our previous results, the lack of expression of some essential homing-related molecules (HRMs) on HS/PCs from UCB, which lead to poor SDF-1a/CXCR-4-mediated transmigration ability, may be one of the reasons for the delayed engraftment after UCBTs. 18 Interestingly, ex vivo manipulation of UCB-or mPB-derived HS/PCs with rHuSCF can upregulate levels of HRMs (including the b1 integrin family members VLA-4, VLA-5, VLA-6, and chemokine receptor CXCR-4) to increase their in vivo homing potential. 18, 21, 23 Thus, it would be of great interest for us to investigate a novel approach, pretreatment of UCBderived HS/PCs with rHuSCF, to enhance the homing potential of transplanted HS/PCs to overcome the disadvantageous CD34 cell dose of UCBT recipients, with a final intention to increase their engraftment. Transplantation of rHuSCF-treated CD34
þ cells from this study demonstrated significantly higher human hematopoietic cell engraftment in NOD/SCID recipients than nontreated ones when 1 Â 10 4 CD34 þ cells were applied. The mechanism of adhesion/homing and transmigration of HSCs within the xenoenvironment has not been fully understood. The chemokine SDF-1a, expressed by both human and murine bone marrow endothelium and stroma, and its cognate receptor, CXCR-4, expressed on human progenitors play a key role. 21 Yet, there is increasing evidence that HS/PCs mobilization and homing is regulated not only by adhesion molecules and chemotactic factors, but more importantly by matrix-degrading enzymes, for example, MMP-2 and MMP-9, that support transendothelial migration across the bone marrow sinusoidal endothelium. [24] [25] [26] MMP-2 and MMP-9 are secreted as the latent forms proMMP-2 and proMMP-9. Once activated, they can degrade denatured collagens (gelatins), native collagen type IV, native collagen typeV, vitronectin and elastin. Growth factors and cytokines induce the production of MMP-2 and MMP-9 in bone marrow CD34 þ cells and stimulate their transmigration through reconstituted basement membrane. 25 Significantly higher human hematopoietic cell engraftment in SCF[ þ ] group NOD/SCID recipients may be due to upregulation levels of MMP-2 and MMP-9 on transplanted HS/PCs as all in vivo homed UCB-derived CD34 þ cells in either SCF [À] or SCF[ þ ] group recipients expressed strongly both MMP-2 and MMP-9 ( Figure 3) , and more importantly, pretreatment of UCB CD34 þ cells with peptide-hydroxamates KB8301 completely blocked human cell engraftment in both SCF [À] and SCF[ þ ] group recipient mice (Figure 4) , indicating the essential roles of MMP-2 and MMP-9 during the process of HS/PCs homing and engragtment. From our results, it could be speculated that in vivo transmigration of HS/PCs is controlled by a variety of HRMs rather than by a single chemokine (e.g. CXCR-4/SDF-1a axis). Trafficking of HS/ PCs may require combined and interactive regulatory functions of these mediators. Pretreatment of human HS/ PCs from UCB with poor SDF-1a/CXCR-4-mediated transmigration ability could induce higher motility to transmigrate through a physiological circulatory system, and engraft in other hematopoietic microenvironment.
In conclusion, using this novel approach, we might shed insight into the mechanism(s) of human HS/PCs homing and their in vivo homing behavior. The identification of the effective strategy and more efficient engraftment of CD34 þ SRCs produced by pretreatment of human HS/PCs with rHuSCF might provide an optimal approach required to develop more effective stem cell-based therapies in situations where engraftment is delayed due to limiting HS/PCs number, for example, UCBTs. 
